Poseida Total Assets from 2010 to 2024

PSTX Stock

USD 9.33 0.05 0.53%

Poseida Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 233.2 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-12-31

Previous Quarter

298.7 M

Current Value

293.6 M

Quarterly Volatility

67.9 M

Covid

Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 9.1 M, Income Tax Expense of 112.3 K or Tax Provision of 112.3 K, as well as many indicators such as Price To Sales Ratio of 4.45, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.

Check out the analysis of Poseida Therapeutics Correlation against competitors.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.

Latest Poseida Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Poseida Therapeutics over the last few years. Total assets refers to the total amount of Poseida Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Poseida Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Poseida Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 273.88 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Poseida Total Assets Regression Statistics

	Arithmetic Mean	126,365,090
	Geometric Mean	67,293,297
	Coefficient Of Variation	106.39
	Mean Deviation	118,471,175
	Median	25,454,000
	Standard Deviation	134,436,199
	Sample Variance	18073.1T
	Range	346M
	R-Value	0.81
	Mean Square Error	6561T
	R-Squared	0.66
	Significance	0.0002
	Slope	24,475,273
	Total Sum of Squares	253023.3T

Poseida Total Assets History

	2024	233.2 M
	2023	273.9 M
	2022	351.8 M
	2021	269.3 M
	2020	371.5 M
	2019	147 M
	2018	45.1 M

Other Fundumenentals of Poseida Therapeutics

Intangibles To Total Assets

Poseida Therapeutics Total Assets component correlations

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Good Will	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Intangible Assets	Deferred Long Term Liab	Capital Stock	Short Term Investments	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.83	0.2	0.61	0.83	0.84	0.72	0.85	0.94	0.69	0.13	0.72	-0.53	0.13	0.95	0.51	0.82	0.81	-0.57	0.71	0.88	0.79	0.61	0.65
Retained Earnings	-0.83		-0.52	-0.75	-0.85	-0.93	-0.8	-0.88	-0.7	-0.82	-0.07	-0.93	0.68	-0.58	-0.76	-0.78	-0.82	-0.84	0.84	-0.9	-0.94	-0.69	-0.79	-0.84
Accounts Payable	0.2	-0.52		0.05	0.4	0.4	0.79	0.43	0.19	0.17	-0.7	0.4	-0.18	0.53	0.23	0.6	0.37	0.6	-0.61	0.32	0.35	-0.16	0.12	0.21
Net Receivables	0.61	-0.75	0.05		0.56	0.79	0.33	0.56	0.45	0.7	0.53	0.84	-0.55	0.36	0.53	0.44	0.49	0.46	-0.45	0.9	0.83	0.68	0.98	0.94
Total Current Assets	0.83	-0.85	0.4	0.56		0.91	0.82	1.0	0.86	0.81	-0.13	0.87	-0.3	0.56	0.9	0.82	0.99	0.92	-0.82	0.6	0.88	0.81	0.6	0.58
Common Stock	0.84	-0.93	0.4	0.79	0.91		0.79	0.91	0.8	0.86	0.06	0.96	-0.42	0.49	0.86	0.8	0.86	0.84	-0.78	0.8	0.99	0.77	0.85	0.84
Property Plant Equipment	0.72	-0.8	0.79	0.33	0.82	0.79		0.83	0.75	0.52	-0.51	0.69	-0.25	0.42	0.77	0.74	0.8	0.91	-0.74	0.53	0.75	0.38	0.4	0.46
Total Assets	0.85	-0.88	0.43	0.56	1.0	0.91	0.83		0.86	0.81	-0.12	0.87	-0.34	0.55	0.9	0.82	0.99	0.93	-0.83	0.63	0.89	0.8	0.6	0.6
Total Stockholder Equity	0.94	-0.7	0.19	0.45	0.86	0.8	0.75	0.86		0.59	-0.08	0.64	-0.21	0.06	0.99	0.52	0.86	0.85	-0.52	0.51	0.8	0.76	0.47	0.46
Current Deferred Revenue	0.69	-0.82	0.17	0.7	0.81	0.86	0.52	0.81	0.59		0.31	0.89	-0.5	0.63	0.66	0.83	0.78	0.61	-0.83	0.67	0.84	0.86	0.78	0.79
Net Debt	0.13	-0.07	-0.7	0.53	-0.13	0.06	-0.51	-0.12	-0.08	0.31		0.14	-0.49	-0.11	-0.05	-0.21	-0.13	-0.32	0.14	0.37	0.14	0.43	0.46	0.44
Long Term Debt	0.72	-0.93	0.4	0.84	0.87	0.96	0.69	0.87	0.64	0.89	0.14		-0.47	0.66	0.72	0.84	0.82	0.77	-0.83	0.84	0.95	0.75	0.89	0.87
Good Will	-0.53	0.68	-0.18	-0.55	-0.3	-0.42	-0.25	-0.34	-0.21	-0.5	-0.49	-0.47		-0.32	-0.26	-0.27	-0.29	-0.28	0.44	-0.78	-0.51	-0.4	-0.52	-0.66
Total Liab	0.13	-0.58	0.53	0.36	0.56	0.49	0.42	0.55	0.06	0.63	-0.11	0.66	-0.32		0.15	0.77	0.55	0.43	-0.79	0.4	0.43	0.34	0.42	0.43
Net Invested Capital	0.95	-0.76	0.23	0.53	0.9	0.86	0.77	0.9	0.99	0.66	-0.05	0.72	-0.26	0.15		0.59	0.89	0.88	-0.59	0.58	0.86	0.79	0.55	0.54
Short Long Term Debt	0.51	-0.78	0.6	0.44	0.82	0.8	0.74	0.82	0.52	0.83	-0.21	0.84	-0.27	0.77	0.59		0.79	0.76	-0.97	0.51	0.73	0.56	0.54	0.55
Net Working Capital	0.82	-0.82	0.37	0.49	0.99	0.86	0.8	0.99	0.86	0.78	-0.13	0.82	-0.29	0.55	0.89	0.79		0.92	-0.81	0.55	0.83	0.81	0.53	0.51
Short Term Debt	0.81	-0.84	0.6	0.46	0.92	0.84	0.91	0.93	0.85	0.61	-0.32	0.77	-0.28	0.43	0.88	0.76	0.92		-0.79	0.61	0.82	0.6	0.47	0.48
Intangible Assets	-0.57	0.84	-0.61	-0.45	-0.82	-0.78	-0.74	-0.83	-0.52	-0.83	0.14	-0.83	0.44	-0.79	-0.59	-0.97	-0.81	-0.79		-0.6	-0.73	-0.58	-0.53	-0.56
Deferred Long Term Liab	0.71	-0.9	0.32	0.9	0.6	0.8	0.53	0.63	0.51	0.67	0.37	0.84	-0.78	0.4	0.58	0.51	0.55	0.61	-0.6		0.86	0.59	0.88	0.92
Capital Stock	0.88	-0.94	0.35	0.83	0.88	0.99	0.75	0.89	0.8	0.84	0.14	0.95	-0.51	0.43	0.86	0.73	0.83	0.82	-0.73	0.86		0.79	0.87	0.88
Short Term Investments	0.79	-0.69	-0.16	0.68	0.81	0.77	0.38	0.8	0.76	0.86	0.43	0.75	-0.4	0.34	0.79	0.56	0.81	0.6	-0.58	0.59	0.79		0.68	0.63
Long Term Debt Total	0.61	-0.79	0.12	0.98	0.6	0.85	0.4	0.6	0.47	0.78	0.46	0.89	-0.52	0.42	0.55	0.54	0.53	0.47	-0.53	0.88	0.87	0.68		0.97
Capital Surpluse	0.65	-0.84	0.21	0.94	0.58	0.84	0.46	0.6	0.46	0.79	0.44	0.87	-0.66	0.43	0.54	0.55	0.51	0.48	-0.56	0.92	0.88	0.63	0.97

Click cells to compare fundamentals

About Poseida Therapeutics Financial Statements

Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	273.9 M	233.2 M
Intangibles To Total Assets	0.02	0.02

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC